Paritaprevir is a direct acting antiviral agent used in combination with other antiviral agents for the treatment of Hepatitis C Virus (HCV) infections. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients.
- Mechanism
- Curator reviewed
Paritaprevir is a potent inhibitor of the NS3/4A serine protease of Hepatitis C Virus (HCV). Following viral replication of HCV genetic material and translation into a single polypeptide, Nonstructural Protein 3 (NS3) and its activating cofactor Nonstructural Protein 4A (NS4A) are responsible for cleaving it into the following structural and nonstructural proteins required for assembly into mature virus: NS3, NS4A, NS4B, NS5A, and NS5B. By inhibiting viral protease NS3/4A, paritaprevir therefore prevents viral replication and function.
- Primary indication
- When used within the fixed-dose combination product with DB09296, DB09183, and DB00503 as the FDA-approved product Viekira Pak, paritaprevir is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and...Curator reviewed · 5 structured indications
- Formula / weight
- C40H43N7O7S · 765.89 g/mol (avg)
- First approval
- Canada, 2014 · United States, 2014
- Also known as
- Veruprevir
- Code names
- ABT-450
- Brand names
Resolves to
UAUIUKWPKRJZJV-QPLHLKROSA-NSMILES[H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](CN1C(=O)[C@H](CCCCC\C=C/2)NC(=O)C1=CN=C(C)C=N1)OC1=NC2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)NS(=O)(=O)C1CC1What you can answer from here — as of August 30, 2026
Which drugs share a target with Paritaprevir, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account